(S,R,R,R)-Orlistat

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S,R,R,R)-Orlistat
• 英文别名: 1-(3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamido-4-methylpentanoate
• 化学式: C₂₉H₅₃NO₅
• 分子量: 495.7
• InChiKey: AHLBNYSZXLDEJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  35
• 可旋转键数：
  23
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PREPARATION OF TETRAHYDROLIPSTATIN BY HYDROGENATION OF LIPSTATIN, SOLVENT EXTRACTION AND PURIFICATION<br/>[FR] PREPARATION DE TETRAHYDROLIPSTATINE PAR HYDROGENATION DE LIPSTATINE, EXTRACTION PAR SOLVANT ET PURIFICATION
  申请人：BIOCON LTD

  公开号：WO2005007639A1

  公开（公告）日：2005-01-27

  A process for obtaining substantially pure tetrahydrolipstatin (Orlistat) by a) extraction of a water miscible layer containing lipstatin with a water immiscible solvent, b) concentration of the water immiscible layer, c) extraction of the concentrate with a water miscible solvent, d) catalytic hydrogenation of the water miscible layer to afford tetrahydrolipstatin, e) filtration of the mixture from (d), f) treating with water or water miscible solvent, g) extraction with water immiscible solvent and concentration, h) affording tetrahydrolipstatin, i) treating with water miscible solvent to afford pharmaceutical pure tetrahydrolipstatin.

  一种获得几乎纯的四氢利福平（奥利司他）的方法，包括a）用一种水不相容的溶剂从含有脂肪酸酯酶抑制剂的水相中提取脂肪酸酯酶抑制剂，b）浓缩水不相容层，c）用水相溶剂提取浓缩物，d）催化氢化水相层以得到四氢利福平，e）过滤（d）混合物，f）用水或水相溶剂处理，g）用水不相容溶剂提取和浓缩，h）得到四氢利福平，i）用水相溶剂处理以得到纯的药用四氢利福平。
• UNDIFFERENTIATED STEM CELL-REMOVING AGENT, AND METHOD FOR REMOVING UNDIFFERENTIATED STEM CELLS
  申请人：Keio University

  公开号：EP3527657A1

  公开（公告）日：2019-08-21

  An undifferentiated stem cell-removing agent which contains at least one kind selected from the group consisting of a fatty acid synthesis inhibitor, a fatty acid utilization inhibitor, and a cholesterol synthesis inhibitor; a method for removing undifferentiated stem cells which includes culturing a cell mixture that contains an undifferentiated stem cell and a differentiated cell in the presence of the undifferentiated stem cell-removing agent; and a production method of cells for transplantation which includes the following steps (i) and (ii): a step (i) of inducing a desired differentiated cell from an undifferentiated stem cell, and a step (ii) of culturing the cell mixture obtained in the step (i) in the presence of the undifferentiated stem cell-removing agent are provided.

  一种未分化干细胞去除剂，它含有至少一种选自由脂肪酸合成抑制剂、脂肪酸利用抑制剂和胆固醇合成抑制剂组成的组；一种去除未分化干细胞的方法，它包括在未分化干细胞去除剂存在下培养含有未分化干细胞和已分化细胞的细胞混合物；以及一种用于移植的细胞的生产方法，它包括以下步骤(i)和(ii)：步骤(i)从未分化干细胞中诱导出所需的分化细胞，步骤(ii)在未分化干细胞去除剂存在下培养步骤(i)中获得的细胞混合物。
• COMBINED DRUG ADMINISTRATION
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2373344A1

  公开（公告）日：2011-10-12
• NOVEL COMBINED ADMINISTRATION
  申请人：Gross Guenter

  公开号：US20100144853A1

  公开（公告）日：2010-06-10

  The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder.
• COMBINED DRUG ADMINISTRATION OF DALCETRAPIB AND ORLISTAT
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160074360A1

  公开（公告）日：2016-03-17

  The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder.